Multiple myeloma

Plasma cells normally make antibodies. In myeloma, one abnormal plasma-cell population expands in marrow and may produce a monoclonal protein or free light chains. These cells and proteins can damage organs as well as interfere with blood production.

Diagnosis uses blood and urine tests, marrow findings and imaging. MGUS and smoldering myeloma are related conditions that do not automatically require the same treatment as active myeloma. Clinical criteria and risk assessment determine the next step.

Acquired genetic changes in plasma cells affect their growth and interactions with the marrow environment. Myeloma usually develops through a precursor state, often previously undetected.

It is more common in older adults, and risk varies among populations and families, but most people have no identifiable preventable cause. It is not contagious. A mutation found in myeloma cells does not automatically mean an inherited disorder.

Myeloma can weaken bone, causing pain or fractures, and may raise blood calcium. Anemia can cause fatigue and breathlessness. Abnormal light chains and other effects can impair kidney function.

Normal antibody production can be reduced, increasing infection risk. Some patients have few symptoms at diagnosis, so treatment decisions use laboratory and imaging evidence of organ damage or other myeloma-defining features, not symptoms alone.

Initial therapy commonly combines several medicine classes, including a proteasome inhibitor, an immunomodulatory medicine, a steroid and often an anti-CD38 antibody. The regimen is adapted to medical fitness, kidney function, disease risk and access.

For eligible patients, high-dose melphalan followed by autologous stem cell rescue can deepen and prolong disease control. The cells are collected beforehand from the patient. Timing and maintenance treatment are individualized; an autologous transplant is not a guaranteed cure.

Relapsed disease may be treated with different combinations, CAR-T therapy, bispecific antibodies or clinical trials. Allogeneic transplantation has a much narrower role because its risks must be weighed against these alternatives and it is not standard routine myeloma care.

Care may involve long periods of treatment and monitoring, with attention to bone health, kidney function, infection prevention, pain and mobility. The burden is not measured only by the monoclonal protein level.

Autologous transplantation includes cell collection, high-dose chemotherapy and recovery from low blood counts. CAR-T therapy follows a different process and has its own immune and neurological risks. Rehabilitation and practical support may be needed with either approach.

The usual myeloma transplant uses the patient’s own blood-forming cells. Approved autologous CAR-T therapies also begin with the patient’s cells, but they modify T cells to recognize the cancer. These are different treatments, and neither uses a registry donor.

A donor is relevant only in the uncommon situation where allogeneic transplantation is selected. Registry recruitment supports patients across many diseases and should not suggest that the typical person receiving a myeloma transplant needs an unrelated marrow match.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?